Project Grant R01CA298083
Award Date 8/18/25
Completion Date 7/31/30
Dollars Obligated $485K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Minnesota, USA
Similar Awards
- This federal Project Grant award of $460,940.00 was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The award will support research at The University of Texas M.D. Anderson Cancer Center to investigate the impact of glioma-associated germline risk alleles on neurodevelopmental trajectories. The goal is to clarify how certain genetic variants associated...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) is providing $997,410 to Arizona State University (ASU) to conduct research aimed at detecting and differentiating invasive subtypes of high-grade glioma brain tumors using MRI. The goal is to develop non-invasive methods to spatially resolve clusters of the neuronal (NEU) and glycolytic/plurimetabolic (GPM) subtypes of infiltrative tumor cells, which are not detected by...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $1,064,642 to Tufts Medical Center Parent, Inc. to conduct research on the role of the angiogenin (ANG) and plexin-B2 (PLXNB2) signaling pathway in regulating glioma stem cell properties and preventing recurrence of glioblastoma (GBM), a deadly form of brain cancer. The research aims to characterize how the ANG-PLXNB2 axis promotes small RNA biogenesis, particularly tRNA-derived...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $652,751 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to Mayo Clinic to develop antibody drug conjugates (ADCs) designed to enhance the therapeutic window for treating glioblastoma (GBM), the most common and lethal primary brain cancer. The 5-year project, running from August 2025 to April 2030, will build on Mayo Clinic's previous research...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $639,004 to Mayo Clinic from January 1, 2025 to December 31, 2029 to conduct research on using a novel long-acting interleukin-7 (NT-I7) in combination with anti-PD-1 checkpoint blockade for the treatment of glioblastoma. The key products and services to be delivered under this award include: Collecting and processing pre- and post-treatment tumor tissue and peripheral blood samples...
- The federal Project Grant award of $2,820,337, awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) on August 6, 2025, supports research to develop new methods for directly measuring and interrupting metabolic pathways in glioblastoma brain cancers. The project, led by researchers at the University of Michigan, aims to: 1) create new techniques to directly measure metabolic activity in mouse models and glioblastoma patients, and 2) conduct a clinical trial to...
- The National Cancer Institute (NCI) awarded a $266,736 Cooperative Agreement to the Mayo Clinic in Rochester, Minnesota under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The award, effective August 1, 2025 through July 31, 2026, will support research to validate assays for cell-free DNA amplified DNA junctions to monitor high-grade glioma. As a renowned non-profit academic medical center, Mayo Clinic will leverage its expertise in medical research, clinical trials, and...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to the Mayo Clinic Jacksonville (a nonprofit corporation registered as Scott Lynch MD) to develop a first-in-class non-muscle myosin II (NMII) inhibitor, MT-125, for the treatment of glioblastoma. The $607,634 award, effective January 1, 2025 through December 31, 2029, supports research to uncover the mechanisms behind the synergistic effects of MT-125 when combined with...
- This Project Grant award of $442,750.00 was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The funding will support research at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to investigate the role of extrachromosomal DNA (ecDNA) in glioblastoma (GBM), a deadly form of brain cancer. The research aims to: 1) determine...
- The National Cancer Institute (NCI) awarded a $455,111 Project Grant under CFDA 93.393 "Cancer Cause and Prevention Research" to the Sloan-Kettering Institute for Cancer Research in New York. The 2-year grant, awarded on September 5, 2023, will support research to "Leverage the Hidden Genome to Recover the Missing Heritability of Cancer." The project aims to 1) estimate additional heritability that can be explained by the "hidden genome" (regions of unknown...